BINEX Stock Forecast for 2023 - 2025 - 2030
Updated on 04/27/2024
BINEX Stock Forecast and Price Target
Given the average yearlong price target of ₩5515.13 provided by prominent analysts over the past few months, there is a potential downside of approximately -59.12% from the last closing price in April, 2024 for BINEX's stock if it is reached. This estimation is based on a high estimate of ₩6176.94 and a low estimate of ₩4908.46. Even if you are not interested in A053030 stock, it is still imperative to be aware of its competitors.
-59.12% Downside
BINEX Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, BINEX's Price has decreased by 100.00%, from ₩8209.18 to ₩0.00. In the next year, analysts believe that Fair Value will reach ₩11.03k – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A128940 Stock Forecast | Hanmi Pharm. | Outperform |
18
|
₩310.50k | Buy/Sell | ₩382.71k | 33.66% |
| A008930 Stock Forecast | Hanmi Science | - |
14
|
₩42.55k | Buy/Sell | ₩0.00 | -100.00% |
| A000250 Stock Forecast | Sam Chun Dang Pharm. | - |
6
|
₩106.60k | Buy/Sell | ₩80.00k | -100.00% |
| A145020 Stock Forecast | Hugel | Buy |
16
|
₩208.00k | Buy/Sell | ₩201.75k | 5.29% |
| A009420 Stock Forecast | Hanall Biopharma | Buy |
14
|
₩34.75k | Buy/Sell | ₩44.67k | 29.50% |
BINEX Revenue Forecast for 2023 - 2025 - 2030
BINEX's Revenue has seen impressive growth In the last two years, rising from ₩132.98B to ₩156.68B – a growth of 17.82%. In the next year, analysts believe that Revenue will reach ₩200.90B – an increase of 28.23%. For the next seven years, the forecast is for Revenue to grow by 91.41%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A019170 Stock Forecast | Shinpoong Pharmaceutical Co.,L... | - |
14
|
₩12.96k | Buy/Sell | ₩0.00 | -100.00% |
| A069620 Stock Forecast | Daewoong pharmaceutical Co.,Lt... | Buy |
16
|
₩112.70k | Buy/Sell | ₩156.10k | 37.53% |
| A185750 Stock Forecast | Chong Kun Dang Pharmaceutical | Outperform |
16
|
₩101.10k | Buy/Sell | ₩124.29k | 48.37% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A005250 Stock Forecast | Green Cross Holdings | - |
16
|
₩16.17k | Buy/Sell | ₩0.00 | -100.00% |
| A001060 Stock Forecast | JW Pharmaceutical | Buy |
14
|
₩30.40k | Buy/Sell | ₩40.62k | 38.16% |
| A003850 Stock Forecast | Boryung | Buy |
17
|
₩10.93k | Buy/Sell | ₩13.50k | 46.39% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A086450 Stock Forecast | DongKook Pharmaceutical | Buy |
16
|
₩16.28k | Buy/Sell | ₩20.00k | 47.42% |
| A003090 Stock Forecast | Daewoong | Outperform |
14
|
₩18.18k | Buy/Sell | ₩38.00k | 37.51% |
| A000640 Stock Forecast | Dong-A Socio Holdings | - |
13
|
₩110.20k | Buy/Sell | ₩0.00 | -100.00% |
BINEX EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, BINEX's EBITDA has seen an increase, rising from ₩21.82B to ₩25.48B. This represents a growth of 16.79%. Analysts predict that BINEX's EBITDA will increase in the upcoming year, reaching ₩46.00B. This would represent an increase of 80.53%. Over the next seven years, experts predict that BINEX's EBITDA will grow at a rate of 59.95%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A170900 Stock Forecast | Dong-A ST | Outperform |
17
|
₩67.50k | Buy/Sell | ₩74.50k | 20.74% |
| A058820 Stock Forecast | CMG Pharmaceutical | - |
14
|
₩2.24k | Buy/Sell | ₩0.00 | -100.00% |
| A140410 Stock Forecast | Mezzion Pharma | - |
6
|
₩36.55k | Buy/Sell | ₩0.00 | -100.00% |
BINEX EBIT Forecast for 2023 - 2025 - 2030
BINEX's EBIT has seen growth In the last two years, going from ₩16.14B to ₩17.18B – a gain of 6.44% In the next year, analysts believe that EBIT will reach ₩35.00B – an increase of 103.74%. For the next seven years, the forecast is forEBIT to grow by 291.17%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A102460 Stock Forecast | REYON Pharmaceutical | - |
15
|
₩15.75k | Buy/Sell | ₩0.00 | -100.00% |
| A047920 Stock Forecast | HLB Pharmaceutical | - |
4
|
₩34.90k | Buy/Sell | ₩0.00 | -100.00% |
| A007570 Stock Forecast | Ilyang Pharmaceutical Co.,Ltd | - |
13
|
₩14.56k | Buy/Sell | ₩0.00 | -100.00% |
BINEX EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, BINEX's EPS has decreased by 100.00%, from ₩614.00 to ₩0.00. In the next year, analysts believe that EPS will reach ₩825.00 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A003000 Stock Forecast | Bukwang Pharmaceutical | - |
10
|
₩6.15k | Buy/Sell | ₩17.66k | -100.00% |
| A249420 Stock Forecast | Ildong Pharmaceutical | Outperform |
12
|
₩15.28k | Buy/Sell | ₩23.00k | 63.61% |
| A243070 Stock Forecast | Huons | Outperform |
18
|
₩34.35k | Buy/Sell | ₩45.00k | 57.21% |
.jpg)